Vanguard Group’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$53.8M Sell
15,958,196
-113,810
-0.7% -$296K ﹤0.01% 2126
2025
Q3
$21.1M Sell
16,072,006
-130,123
-0.8% -$135K ﹤0.01% 2594
2025
Q2
$11.6M Buy
16,202,129
+505,968
+3% +$397K ﹤0.01% 2819
2025
Q1
$23.1M Sell
15,696,161
-3,842,394
-20% -$9.15M ﹤0.01% 2447
2024
Q4
$86.6M Sell
19,538,555
-2,499,542
-11% -$10.1M ﹤0.01% 1931
2024
Q3
$90.8M Buy
22,038,097
+474,683
+2% +$2.55M ﹤0.01% 1917
2024
Q2
$141M Buy
21,563,414
+2,042,048
+10% +$14.4M ﹤0.01% 1680
2024
Q1
$170M Buy
19,521,366
+3,487,821
+22% +$42.3M ﹤0.01% 1611
2023
Q4
$183M Buy
16,033,545
+1,137,845
+8% +$11.3M ﹤0.01% 1555
2023
Q3
$143M Buy
14,895,700
+49,160
+0.3% +$482K ﹤0.01% 1607
2023
Q2
$158M Sell
14,846,540
-127,776
-0.9% -$1.37M ﹤0.01% 1590
2023
Q1
$158M Buy
14,974,316
+241,747
+2% +$2.71M ﹤0.01% 1581
2022
Q4
$183M Buy
14,732,569
+248,012
+2% +$2.81M 0.01% 1480
2022
Q3
$150M Buy
14,484,557
+4,733
+0% +$53.7K ﹤0.01% 1559
2022
Q2
$167M Buy
14,479,824
+1,123,496
+8% +$13.2M ﹤0.01% 1538
2022
Q1
$168M Sell
13,356,328
-131,434
-1% -$1.51M ﹤0.01% 1655
2021
Q4
$157M Buy
13,487,762
+31,629
+0.2% +$388K ﹤0.01% 1734
2021
Q3
$176M Sell
13,456,133
-441,046
-3% -$5.7M ﹤0.01% 1683
2021
Q2
$179M Sell
13,897,179
-1,800,541
-11% -$20.6M ﹤0.01% 1688
2021
Q1
$176M Sell
15,697,720
-194,627
-1% -$2.06M ﹤0.01% 1653
2020
Q4
$181M Buy
15,892,347
+133,929
+0.8% +$1.47M 0.01% 1517
2020
Q3
$142M Sell
15,758,418
-607,919
-4% -$6.04M ﹤0.01% 1491
2020
Q2
$169M Buy
16,366,337
+25,147
+0.2% +$257K 0.01% 1383
2020
Q1
$165M Sell
16,341,190
-297,751
-2% -$3.5M 0.01% 1242
2019
Q4
$221M Sell
16,638,941
-106,232
-0.6% -$1.17M 0.01% 1329
2019
Q3
$144M Buy
16,745,173
+1,139,016
+7% +$11.1M 0.01% 1535
2019
Q2
$171M Sell
15,606,157
-2,233,712
-13% -$25M 0.01% 1458
2019
Q1
$202M Buy
17,839,869
+1,887,368
+12% +$21.1M 0.01% 1334
2018
Q4
$138M Buy
15,952,501
+1,236,506
+8% +$14.2M 0.01% 1476
2018
Q3
$228M Buy
14,715,995
+450,349
+3% +$7.12M 0.01% 1288
2018
Q2
$228M Buy
14,265,646
+558,069
+4% +$8.26M 0.01% 1263
2018
Q1
$177M Buy
13,707,577
+245,478
+2% +$3.06M 0.01% 1365
2017
Q4
$169M Buy
13,462,099
+309,327
+2% +$4.04M 0.01% 1412
2017
Q3
$174M Buy
13,152,772
+303,103
+2% +$4.17M 0.01% 1372
2017
Q2
$203M Buy
12,849,669
+306,149
+2% +$4.45M 0.01% 1222
2017
Q1
$179M Buy
12,543,520
+671,241
+6% +$9.18M 0.01% 1289
2016
Q4
$152M Buy
11,872,279
+340,229
+3% +$4.3M 0.01% 1356
2016
Q3
$153M Buy
11,532,050
+332,897
+3% +$3.89M 0.01% 1284
2016
Q2
$123M Buy
11,199,153
+336,300
+3% +$3.29M 0.01% 1371
2016
Q1
$99.5M Buy
10,862,853
+342,730
+3% +$2.83M 0.01% 1488
2015
Q4
$102M Buy
10,520,123
+312,488
+3% +$3.02M 0.01% 1458
2015
Q3
$89.1M Buy
10,207,635
+280,191
+3% +$2.61M 0.01% 1513
2015
Q2
$100M Buy
9,927,444
+378,064
+4% +$4.39M 0.01% 1525
2015
Q1
$128M Buy
9,549,380
+542,146
+6% +$7.11M 0.01% 1330
2014
Q4
$116M Buy
9,007,234
+271,671
+3% +$3.11M 0.01% 1316
2014
Q3
$94.8M Buy
8,735,563
+137,801
+2% +$1.58M 0.01% 1391
2014
Q2
$110M Buy
8,597,762
+65,707
+0.8% +$714K 0.01% 1328
2014
Q1
$88M Buy
8,532,055
+1,764,732
+26% +$19.8M 0.01% 1439
2013
Q4
$65.8M Buy
6,767,323
+209,118
+3% +$1.88M 0.01% 1609
2013
Q3
$65.1M Buy
6,558,205
+405,586
+7% +$3.98M 0.01% 1542
2013
Q2
$51.3M Buy
+6,152,619
New +$74.6M 0.01% 1619

Other funds holding IRWD

Vanguard Group's IRWD Position: Q4 2025 in Review

Vanguard Group reduced its Ironwood Pharmaceuticals (IRWD) stake by 0.71% in Q4 2025, selling an estimated $296K and leaving 15,958,196 shares worth $53.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2126.

Vanguard Group first reported a position in IRWD in Q2 2013 and has held it in 51 quarters since. The position peaked at $228M in Q2 2018. 199 funds tracked by Wall St. Rank hold IRWD as of Q4 2025.

  • Vanguard Group held 15,958,196 shares of Ironwood Pharmaceuticals worth $53.8M as of Q4 2025.
  • Vanguard Group sold 113,810 Ironwood Pharmaceuticals shares in Q4 2025, an estimated $296K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2126 holding.
  • Vanguard Group first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's Ironwood Pharmaceuticals position peaked at $228M in Q2 2018.
  • 199 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.